​

Nurix Therapeutics (NRIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

NRIX Stock Forecast

Nurix Therapeutics stock forecast is as follows: an average price target of $32.67 (represents a 64.75% upside from NRIX’s last price of $19.83) and a rating consensus of 'Buy', based on 19 wall street analysts offering a 1-year stock forecast.

NRIX Price Target

The average price target for Nurix Therapeutics (NRIX) is $32.67 based on 1-year price targets from 19 Wall Street analysts in the past 3 months, with a price target range of $41.00 to $26.00. This represents a potential 64.75% upside from NRIX's last price of $19.83.

NRIX Analyst Ratings

Buy

According to 19 Wall Street analysts, Nurix Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for NRIX stock is 0 'Strong Buy' (0.00%), 15 'Buy' (78.95%), 4 'Hold' (21.05%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Nurix Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2024Etzer DaroutBMO Capital$35.00$20.0674.48%76.50%
Oct 24, 2024David DaiUBS$35.00$24.7841.24%76.50%
Oct 21, 2024Robert BurnsH.C. Wainwright$30.00$25.1919.09%51.29%
Oct 15, 2024Matthew BieglerOppenheimer$35.00$24.8740.73%76.50%
Oct 15, 2024Derek ArchilaWells Fargo$32.00$25.1627.19%61.37%
Oct 14, 2024Stephen WilleyStifel Nicolaus$34.00$24.9836.11%71.46%
Oct 11, 2024Roger SongJefferies$41.00$23.0477.96%106.76%
Sep 05, 2024Brian SkorneyRobert W. Baird$26.00$24.446.38%31.11%
Aug 14, 2024Matthew BieglerOppenheimer$27.00$21.9223.18%36.16%
Jun 27, 2024Gregory RenzaRBC Capital$26.00$20.7025.60%31.11%
Jun 18, 2024Robert BurnsH.C. Wainwright$26.00$18.4441.00%31.11%
Jun 05, 2024Tyler Van BurenPiper Sandler$35.00$15.95119.44%76.50%
Apr 11, 2024Gregory RenzaRBC Capital$23.00$15.6946.59%15.99%
Apr 11, 2024Joel BeattyRobert W. Baird$25.00$15.6959.34%26.07%
Dec 13, 2022Leerink Partners$28.00$12.26128.38%41.20%
May 31, 2022Derek ArchilaWells Fargo$25.00$10.09147.77%26.07%

The latest Nurix Therapeutics stock forecast, released on Dec 05, 2024 by Etzer Darout from BMO Capital, set a price target of $35.00, which represents a 74.48% increase from the stock price at the time of the forecast ($20.06), and a 76.50% increase from NRIX last price ($19.83).

Nurix Therapeutics Price Target by Period

1M3M12M
# Anlaysts1714
Avg Price Target$35.00$34.57$30.71
Last Closing Price$19.83$19.83$19.83
Upside/Downside76.50%74.33%54.87%

In the current month, the average price target of Nurix Therapeutics stock is $35.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 76.50% increase as opposed to Nurix Therapeutics's last price of $19.83. This month's average price target is up 1.24% compared to last quarter, and up 13.97% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 05, 2024BMO CapitalOutperformInitialise
Oct 21, 2024H.C. WainwrightBuyBuyHold
Oct 15, 2024OppenheimerOutperformOutperformHold
Oct 15, 2024Wells FargoOverweightOverweightHold
Oct 14, 2024RBC CapitalOutperformOutperformHold
Oct 14, 2024Piper SandlerOverweightOverweightHold
Oct 11, 2024JefferiesBuyInitialise
Sep 04, 2024RBC CapitalBuyBuyHold
Sep 04, 2024OppenheimerUnderperformUnderperformHold
Sep 04, 2024OppenheimerOutperformOutperformHold
Aug 14, 2024OppenheimerOutperformOutperformHold
Jul 31, 2024StephensBuyBuyHold
Jul 31, 2024RBC CapitalUnderperformUnderperformHold
Jul 15, 2024BarclaysOverweightOverweightHold
Jul 14, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jul 12, 2024OppenheimerOutperformOutperformHold
Jul 12, 2024RBC CapitalOutperformOutperformHold
Jun 27, 2024RBC CapitalUnderperformUnderperformHold
Jun 27, 2024StephensBuyBuyHold
Jun 18, 2024H.C. WainwrightBuyBuyHold
Jun 11, 2024RBC CapitalOutperformOutperformHold
Jun 05, 2024RBC CapitalUnderperformUnderperformHold
Jun 05, 2024StephensBuyBuyHold
Jun 05, 2024Piper SandlerOverweightOverweightHold
May 14, 2024Wells FargoBuyBuyHold
May 14, 2024StephensUnderperformUnderperformHold
May 13, 2024StephensOverweightInitialise
Apr 02, 2024Wells FargoBuyBuyHold
Apr 02, 2024RBC CapitalUnderperformUnderperformHold
Mar 11, 2024RBC CapitalUnderperformUnderperformHold
Mar 11, 2024Wells FargoBuyBuyHold
Feb 16, 2024RBC CapitalUnderperformUnderperformHold
Feb 16, 2024Wells FargoBuyBuyHold
Dec 13, 2022SVB LeerinkOutperformOutperformHold
Oct 11, 2022CitigroupNeutralInitialise
Oct 11, 2022UBSBuyInitialise
Oct 11, 2022Cowen & Co.OutperformInitialise
Oct 11, 2022Maxim GroupBuyInitialise
Oct 11, 2022Canaccord GenuityBuyInitialise
Oct 11, 2022Morgan StanleyUnderweightInitialise
Oct 11, 2022Wolfe ResearchPeer PerformInitialise
Oct 11, 2022WedbushNeutralInitialise
Oct 11, 2022OppenheimerOutperformInitialise
Oct 11, 2022Deutsche BankBuyInitialise
Oct 11, 2022BernsteinMarket PerformInitialise
Oct 11, 2022Wells FargoOverweightUnderweightInitialise
May 31, 2022Wells FargoOverweightUpgrade

Nurix Therapeutics's last stock rating was published by BMO Capital on Dec 05, 2024. The company Initialise its NRIX rating from "null" to "Outperform".

Nurix Therapeutics Financial Forecast

Nurix Therapeutics Revenue Forecast

Dec 25Aug 25May 25Mar 25Dec 24Aug 24May 24Mar 24Dec 23Aug 23May 23Mar 23Dec 22Aug 22May 22Mar 22Dec 21Aug 21May 21Mar 21Dec 20Aug 20
Revenue---------$18.47M$30.68M--$10.79M$11.43M--$10.25M$7.09M--$4.08M
Avg Forecast$15.18M$14.98M$14.48M$14.48M$14.55M$14.97M$22.11M$17.13M$34.14M$11.94M$26.24M$10.96M$15.02M$12.07M$10.51M$9.27M$13.19M$8.54M$8.23M$8.68M$3.94M$6.35M
High Forecast$18.04M$17.81M$17.21M$14.93M$19.43M$15.42M$22.11M$17.13M$84.62M$14.19M$31.19M$13.03M$18.02M$13.59M$11.82M$10.44M$14.85M$9.61M$9.26M$9.76M$4.44M$7.15M
Low Forecast$13.58M$13.40M$12.95M$13.68M$11.45M$14.52M$22.11M$17.13M$5.99M$10.68M$23.47M$9.80M$12.01M$10.75M$9.35M$8.26M$11.75M$7.61M$7.32M$7.72M$3.51M$5.65M
# Analysts11141053374141619222334356
Surprise %---------1.55%1.17%--0.89%1.09%--1.20%0.86%--0.64%

Nurix Therapeutics's average Quarter revenue forecast for Dec 23 based on 7 analysts is $34.14M, with a low forecast of $5.99M, and a high forecast of $84.62M. NRIX's average Quarter revenue forecast represents a 84.86% increase compared to the company's last Quarter revenue of $18.47M (Aug 23).

Nurix Therapeutics EBITDA Forecast

Dec 25Aug 25May 25Mar 25Dec 24Aug 24May 24Mar 24Dec 23Aug 23May 23Mar 23Dec 22Aug 22May 22Mar 22Dec 21Aug 21May 21Mar 21Dec 20Aug 20
# Analysts11141053374141619222334356
EBITDA---------$-36.63M$-23.43M--$-43.83M$-43.08M--$-28.21M$-25.60M--$-17.97M
Avg Forecast$-14.08M$-13.90M$-13.43M$-13.43M$-13.50M$-13.89M$-20.51M$-51.32M$-31.67M$-11.07M$-24.34M$-46.66M$-28.40M$-11.20M$-9.75M$-36.88M$-12.24M$-7.93M$-7.63M$-14.85M$-3.66M$-11.09M
High Forecast$-12.60M$-12.43M$-12.02M$-12.69M$-10.63M$-13.47M$-20.51M$-41.06M$-5.56M$-9.91M$-21.78M$-37.32M$-22.72M$-9.97M$-8.68M$-29.51M$-10.90M$-7.06M$-6.80M$-11.88M$-3.26M$-8.87M
Low Forecast$-16.74M$-16.52M$-15.97M$-13.85M$-18.03M$-14.31M$-20.51M$-61.59M$-78.51M$-13.17M$-28.94M$-55.99M$-34.08M$-12.60M$-10.97M$-44.26M$-13.78M$-8.92M$-8.59M$-17.82M$-4.12M$-13.30M
Surprise %---------3.31%0.96%--3.91%4.42%--3.56%3.35%--1.62%

undefined analysts predict NRIX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nurix Therapeutics's previous annual EBITDA (undefined) of $NaN.

Nurix Therapeutics Net Income Forecast

Dec 25Aug 25May 25Mar 25Dec 24Aug 24May 24Mar 24Dec 23Aug 23May 23Mar 23Dec 22Aug 22May 22Mar 22Dec 21Aug 21May 21Mar 21Dec 20Aug 20
# Analysts11141053374141619222334356
Net Income---------$-36.98M$-21.79M--$-44.70M$-45.09M--$-28.84M$-26.38M--$-17.84M
Avg Forecast$-51.71M$-50.59M$-48.86M$-48.58M$-49.69M$-50.05M$-46.20M$-54.48M$-36.13M$-61.03M$-41.29M$-49.52M$-31.86M$-68.99M$-70.69M$-39.15M$-49.67M$-45.23M$-38.94M$-15.30M$-38.86M$-11.43M
High Forecast$-44.63M$-43.66M$-42.17M$-47.17M$-37.82M$-43.20M$-39.87M$-43.58M$24.79M$-52.67M$-35.63M$-39.62M$-25.48M$-59.15M$-60.61M$-31.32M$-42.59M$-38.78M$-33.39M$-12.24M$-33.32M$-9.14M
Low Forecast$-64.41M$-63.01M$-60.86M$-51.39M$-65.26M$-62.34M$-57.54M$-65.37M$-72.26M$-76.01M$-51.43M$-59.43M$-38.23M$-80.22M$-82.20M$-46.98M$-57.76M$-52.59M$-45.28M$-18.36M$-45.19M$-13.71M
Surprise %---------0.61%0.53%--0.65%0.64%--0.64%0.68%--1.56%

Nurix Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NRIX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Nurix Therapeutics SG&A Forecast

Dec 25Aug 25May 25Mar 25Dec 24Aug 24May 24Mar 24Dec 23Aug 23May 23Mar 23Dec 22Aug 22May 22Mar 22Dec 21Aug 21May 21Mar 21Dec 20Aug 20
# Analysts11141053374141619222334356
SG&A---------$10.62M$11.68M--$9.75M$9.65M--$8.34M$7.51M--$4.34M
Avg Forecast$11.45M$11.30M$10.92M$10.92M$10.98M$11.30M$16.68M$11.82M$25.76M$9.01M$19.80M$10.74M$7.45M$8.92M$7.76M$8.49M$9.75M$6.31M$6.08M$4.12M$2.91M$2.68M
High Forecast$13.62M$13.44M$12.99M$11.26M$14.66M$11.64M$16.68M$14.18M$63.85M$10.71M$23.54M$12.89M$8.94M$10.03M$8.73M$10.19M$10.97M$7.10M$6.84M$4.94M$3.28M$3.21M
Low Forecast$10.25M$10.11M$9.77M$10.32M$8.64M$10.96M$16.68M$9.46M$4.52M$8.06M$17.71M$8.60M$5.96M$7.94M$6.91M$6.80M$8.68M$5.62M$5.41M$3.29M$2.59M$2.14M
Surprise %---------1.18%0.59%--1.09%1.24%--1.32%1.24%--1.62%

Nurix Therapeutics's average Quarter SG&A projection for Dec 23 is $25.76M, based on 7 Wall Street analysts, with a range of $4.52M to $63.85M. The forecast indicates a 142.48% rise compared to NRIX last annual SG&A of $10.62M (Aug 23).

Nurix Therapeutics EPS Forecast

Dec 25Aug 25May 25Mar 25Dec 24Aug 24May 24Mar 24Dec 23Aug 23May 23Mar 23Dec 22Aug 22May 22Mar 22Dec 21Aug 21May 21Mar 21Dec 20Aug 20
# Analysts11141053374141619222334356
EPS---------$-0.68$-0.40--$-0.88$-1.00--$-0.65$-0.60--$-0.57
Avg Forecast$-0.71$-0.70$-0.67$-0.67$-0.68$-0.69$-0.63$-0.78$-0.50$-0.84$-0.57$-0.87$1.95$-0.95$-0.97$-0.88$-0.68$-0.62$-0.54$-0.45$-0.53$-0.41
High Forecast$-0.61$-0.60$-0.58$-0.65$-0.52$-0.59$-0.55$-0.67$0.34$-0.72$-0.49$-0.75$2.43$-0.81$-0.83$-0.75$-0.59$-0.53$-0.46$-0.39$-0.46$-0.35
Low Forecast$-0.88$-0.87$-0.84$-0.71$-0.90$-0.86$-0.79$-0.97$-0.99$-1.04$-0.71$-1.08$1.69$-1.10$-1.13$-1.02$-0.79$-0.72$-0.62$-0.53$-0.62$-0.48
Surprise %---------0.81%0.71%--0.93%1.03%--1.05%1.12%--1.38%

According to undefined Wall Street analysts, Nurix Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NRIX previous annual EPS of $NaN (undefined).

Nurix Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
STTKShattuck Labs$1.15$12.00943.48%Hold
NKTXNkarta$2.27$21.60851.54%Buy
BDTXBlack Diamond Therapeutics$2.50$20.00700.00%Buy
CCCCC4 Therapeutics$4.05$20.00393.83%Buy
PRLDPrelude Therapeutics$0.89$4.00349.44%Sell
SANASana Bio$1.91$8.00318.85%Buy
RLAYRelay Therapeutics$4.50$18.00300.00%Buy
ARVNArvinas$19.10$58.50206.28%Buy
FHTXFoghorn Therapeutics$5.51$14.00154.08%Buy
PLRXPliant Therapeutics$14.37$35.50147.04%Buy
STOKStoke Therapeutics$12.10$26.50119.01%Buy
NRIXNurix Therapeutics$21.18$32.6754.25%Buy
LYELLyell Immunopharma$0.65$1.0053.85%Hold
KYMRKymera Therapeutics$42.30$58.6038.53%Buy

NRIX Forecast FAQ

Is Nurix Therapeutics a good buy?

Yes, according to 19 Wall Street analysts, Nurix Therapeutics (NRIX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 78.95% of NRIX's total ratings.

What is NRIX's price target?

Nurix Therapeutics (NRIX) average price target is $32.67 with a range of $26 to $41, implying a 64.75% from its last price of $19.83. The data is based on 19 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Nurix Therapeutics stock go up soon?

According to Wall Street analysts' prediction for NRIX stock, the company can go up by 64.75% (from the last price of $19.83 to the average price target of $32.67), up by 106.76% based on the highest stock price target, and up by 31.11% based on the lowest stock price target.

Can Nurix Therapeutics stock reach $30?

NRIX's average twelve months analyst stock price target of $32.67 supports the claim that Nurix Therapeutics can reach $30 in the near future.

What is Nurix Therapeutics's current price target trend?

1 Wall Street analyst forecast a $35 price target for Nurix Therapeutics (NRIX) this month, up 76.50% from its last price of $19.83. Compared to the last 3 and 12 months, the average price target increased by 74.33% and increased by 54.87%, respectively.

Did the NRIX's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Aug 2023), Nurix Therapeutics's revenue was $18.47M, beating the average analysts' forecast of $11.94M by 54.71%. The company's EBITDA was $-36.628M, beating the average prediction of $-11.075M by 230.74%. Nurix Therapeutics's net income was $-36.982M, missing the average estimation of $-61.026M by -39.40%. The company's SG&A was $10.62M, beating the average forecast of $9.01M by 17.95%. Lastly, the company's EPS was $-0.68, missing the average prediction of $-0.839 by -18.90%